Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Asset Writedowns and Impairment (2021 - 2025)

Biote (BTMD) has 5 years of Asset Writedowns and Impairment data on record, last reported at -$169000.0 in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 9.03% year-over-year to -$169000.0; the TTM value through Sep 2025 reached $751000.0, up 2175.76%, while the annual FY2024 figure was $503000.0, 2034.62% up from the prior year.
  • Asset Writedowns and Impairment reached -$169000.0 in Q3 2025 per BTMD's latest filing, down from $327000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $773000.0 in Q1 2025 and bottomed at -$650000.0 in Q4 2023.
  • Average Asset Writedowns and Impairment over 5 years is $120562.5, with a median of $65000.0 recorded in 2022.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 400.0% in 2022, then soared 1004.29% in 2025.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $291000.0 in 2021, then increased by 20.27% to $350000.0 in 2022, then plummeted by 285.71% to -$650000.0 in 2023, then soared by 72.31% to -$180000.0 in 2024, then increased by 6.11% to -$169000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were -$169000.0 in Q3 2025, $327000.0 in Q2 2025, and $773000.0 in Q1 2025.